These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15806322)

  • 41. Osteoporosis management: physicians' recommendations and womens' compliance following osteoporosis testing.
    Cole RP; Palushock S; Haboubi A
    Women Health; 1999; 29(1):101-15. PubMed ID: 10427644
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Osteoporosis treatment and prevention for postmenopausal women: current and future therapeutic options.
    Pinkerton JV; Thomas S; Dalkin AC
    Clin Obstet Gynecol; 2013 Dec; 56(4):711-21. PubMed ID: 24100598
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estimating the causal effect of milk powder supplementation on bone mineral density: a randomized controlled trial with both non-compliance and loss to follow-up.
    Chen Y; Zhang Q; Wang Y; Xiao Y; Fu R; Bao H; Liu M
    Eur J Clin Nutr; 2015 Jul; 69(7):824-30. PubMed ID: 25626413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New developments in the treatment of osteoporosis.
    Eriksen EF; Halse J; Moen MH
    Acta Obstet Gynecol Scand; 2013 Jun; 92(6):620-36. PubMed ID: 22646526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rheumatology: 15. Osteoporosis.
    Wade JP
    CMAJ; 2001 Jul; 165(1):45-50. PubMed ID: 11468955
    [No Abstract]   [Full Text] [Related]  

  • 47. [Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy].
    García-Hernández P; Carranza-Lira S; Motta-Martínez E
    Ginecol Obstet Mex; 2010 Jun; 78(6):322-8. PubMed ID: 20939245
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of postmenopausal osteoporosis.
    Delmas PD
    Lancet; 2002 Jun; 359(9322):2018-26. PubMed ID: 12076571
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association between osteoporosis treatment and severe periodontitis in postmenopausal women.
    Passos-Soares JS; Vianna MIP; Gomes-Filho IS; Cruz SS; Barreto ML; Adan LF; Rösing CK; Trindade SC; Cerqueira EMM; Scannapieco FA
    Menopause; 2017 Jul; 24(7):789-795. PubMed ID: 28225430
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successful direct intervention for osteoporosis in patients with minimal trauma fractures.
    Kuo I; Ong C; Simmons L; Bliuc D; Eisman J; Center J
    Osteoporos Int; 2007 Dec; 18(12):1633-9. PubMed ID: 17603741
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The necessity of cost-effectiveness analysis in osteoporosis].
    Lamy O; Krieg MA
    Rev Med Suisse; 2007 Jun; 3(115):1521-5. PubMed ID: 17682796
    [TBL] [Abstract][Full Text] [Related]  

  • 53. EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis.
    Palacios S; Brincat M; Erel CT; Gambacciani M; Lambrinoudaki I; Moen MH; Schenck-Gustafsson K; Tremollieres F; Vujovic S; Rees M; Rozenberg S
    Maturitas; 2012 Feb; 71(2):194-8. PubMed ID: 22176952
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treatment and prevention of osteoporosis in patients with decreased renal function].
    Vestergaard P; Eiken PA
    Ugeskr Laeger; 2008 Jan; 170(4):227-30. PubMed ID: 18282452
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates.
    Gu T; Eisenberg Lawrence DF; Stephenson JJ; Yu J
    Clin Interv Aging; 2016; 11():1-8. PubMed ID: 26929609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Practice. Postmenopausal Osteoporosis.
    Black DM; Rosen CJ
    N Engl J Med; 2016 Jan; 374(3):254-62. PubMed ID: 26789873
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prescription drug therapies for prevention and treatment of postmenopausal osteoporosis.
    O'Connell MB
    J Manag Care Pharm; 2006 Jul; 12(6 Suppl A):S10-9; quiz S26-8. PubMed ID: 17269853
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-response to osteoporosis treatment.
    Francis RM
    J Br Menopause Soc; 2004 Jun; 10(2):76-80. PubMed ID: 15207030
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Osteoporosis pharmacotherapy and counseling services in US ambulatory care clinics: opportunities for multidisciplinary interventions.
    Teschemaker A; Lee E; Xue Z; Wutoh AK
    Am J Geriatr Pharmacother; 2008 Dec; 6(5):240-8. PubMed ID: 19161926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.